Teriparatide

FDA-approved

Calculate Dose

For research use only.

Key Facts

CAS: 52232-67-4
Molecular Weight (MW): 4117.8 g/mol
Half-life: ~1 hour (sc)
Unit: mcg
Administration Route: Subcutaneous
Frequency: Once daily
Last updated: 12/14/2025
Targets: PTH1 receptorOsteoblastsBone tissue

Overview

—

Protocol

Dosage Range: 20 mcg daily
Frequency: Once daily
Cycle: Maximum 2 years of treatment
Administration Route: Subcutaneous
Reconstitution Guide: Prefilled pen - no reconstitution needed

Science

Mechanism of Action

Teriparatide is a synthetic form of parathyroid hormone (PTH 1-34) that stimulates bone formation by activating osteoblasts. It increases bone mineral density and reduces fracture risk through anabolic bone effects.

Targets

PTH1 receptorOsteoblastsBone tissue

Studies

Teriparatide reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with severe osteoporosis— Journal/year not available

Benefits

Increased bone mineral densityReduced vertebral and nonvertebral fracturesAnabolic bone formationImproved bone microarchitecture

Potential Side Effects

Nausea
Leg cramps
Dizziness
Headache
Orthostatic hypotension
Hypercalcemia
Injection site reactions
Increased risk of osteosarcoma (with long-term use)

References

FDA Label - Forteo
External link · Year —

Related peptides